11 نتایج
FIELD OF THE INVENTION
The present invention relates to a method for promoting the growth of new blood vessels (angiogenesis) especially coronary blood vessels after myocardial infarction.
BACKGROUND OF THE INVENTION
It is estimated that five million people are afflicted with chronic stable angina
INTRODUCTION
The invention relates to a method for treatment of unstable coronary artery disease, which is characterised by an early revascularisation together with administration of a low molecular weight heparin. Preferably the low molecular weight heparin is administered up to
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention concerns an improved therapeutic regimen for the treatment of thrombolytic disorders, such as acute myocardial infarction (AMI). In particular, the present invention concerns the treatment of thrombolytic disorders, e.g. AMI
FIELD OF THE INVENTION
The present invention relates to a treatment for myocardial infarction, and more specifically to a therapy capable of preventing the reocclusion of a coronary artery which often accompanies the use of thrombolytic agents in the treatment of myocardial infarction. The therapy
FIELD OF THE INVENTION
The present invention relates generally to processes for the preparation of low affinity, low molecular weight heparins (LA-LMW-heparins) which are useful, inter alia, as antithrombotics. More particularly, the present invention relates to processes for the preparation of
FIELD OF THE INVENTION
The present invention relates generally to compositions and methods for the treatment of cardiovascular disease. More particularly, the present invention relates to modifying thrombus formation and growth by administering a modified low molecular weight heparin (MLMWH) that,
FIELD OF THE INVENTION
The present invention relates to compositions and methods for treatment of occlusive peripheral vascular disease and coronary diseases, in particular, the occlusion of coronary vessels. More particularly, the invention relates to the promotion of the growth of new blood
FIELD OF THE INVENTION
This invention relates to a method for inhibiting apoptosis in ischemic-reperfused myocardium. More specifically this invention relates to a method for using heparin or noncoagulant heparin in the prevention of apoptosis.
BACKGROUND OF THE INVENTION
Cells die by one of either
The present invention relates to pharmaceutical compositions containing as the active components modified glucosaminoglucans as antithrombotic agents.
The thrombus is an aggregate of platelets and polymorphonuclear leukocytes in a fibrin net and is considered the crucial element causing very serious
STATEMENT OF GOVERNMENTAL SUPPORT
[Not Applicable]
BACKGROUND
Stroke is the leading cause of adult disability in developed countries. There is no therapy that targets the promotion of stroke recovery. As present the only stroke therapy is the administration of tissue plasminogen activator (tPA). TPA
FIELD OF THE INVENTION
The present invention relates in general to SdrG, a fibrinogen-binding bacterial adhesin, and in particular to the use of SdrG or its binding region as an anti-coagulation agent by virtue of its ability to inhibit thrombin-induced fibrin clot formation by interfering with the